Supplementary Table 1. Renal tolerance of TDF in children and adolescents. Literature review (up to December 2019) Author/year of
publication/country (see references)
Design Age
(median or mean)
y
Number of patients on TDF/control
group (total number of
patients if cohort)
TDF exposure
length Tubulopathy
markers Estimated glomerular filtration rate (eGFR)
Papaleo/2007/France Comparative, single center
15.5 44 M: 13 [1-57] + NE
Andiman/2009/USA Comparative, Multicenter cohort study
NI 26 (2102) NI NE NE
TDF related “renal dysfunction”
HR : 2.3 [1.5-3.5]
Riordan/2009/UK Irland Non-comparative Multicenter cohort study
11.8 159 (1253) NI + NE
Judd/2010/UK Irland Partially comparative
Multicenter cohort 2-18 131 (456) Y: 2.1 [1.1-3.0] + eGFR : unchanged
(not comparative) Soler Palacin/2011/Spain Non comparative
Single center
12.5 32 M: 77 [16-143] + Decreased eGFR in 18 patients
Increased creatinine level p<0.001
Pontrelli/2012/Italy Comparative
Single center 13.6 31/49 Y: 0.76 [1-3] + No difference in eGFR
according treatment group 3/23 <90 in TDF + PI group Purswani/2013/USA Comparative
Multicenter cohort study
11.5 95 (448) Y: 0.0 [0.0-2.0] NE Chronic kidney disease
(composite marker) : risk increased for TDF > 3 years, OR : 3.86 [1.06-14.09]
Giaconet/2015/Italy Non-comparative Single center
12.4 26 M: 132 + Creatinine : unchanged
Lim/2015/UK Non-comparative Single center
NI 70 NI + NE
Della Negra/2015/Brazil Initial placebo- controlled phase, open label after 48W Single center
14 45 (placebo
phase) 81 (open labelled)
W48 (placebo base)
W144 (open labelled phase)
+ eGFR : 38/mL/min/1.73m2 at W144
(not evaluated during the randomized phase) Grignolo /2015/Italy Non-comparative
Single center
NI 29 W67 (24-123) NE eGFR :
6mL/min/1.73m2/year Aurpibul/2015/Thaïland Comparative
Two centers
12.2 40/40 96W none eGFR : unchanged
Bunupuradah/2018/Thaïla
nd Comparative
Multicenter cohort 16.7 160 (255) M:10.3 [7.1-12.4] NE Persistent renal dysfunction (incl eGFR)
TDF + PI : aOR 9.6 [3.2-28.9]
NI: not indicated, NE: not evaluated
References 2007-2019 (chronological order)
Papaleo A et al. Increased beta-2 microglobulinuria in human immunodeficiency virus-1-infected children and adolescents treated with tenofovir.
Pediatr Infect Dis J. 2007 Oct;26(10):949-51.
Andiman WA et al. Incidence of persistent renal dysfunction in human immunodeficiency virus-infected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J. 2009 Jul;28(7):619-25.
Riordan A et al. Tenofovir use in humanimmunodeficiency virus-1-infected children in the United kingdom and Ireland.Pediatr Infect Dis J.
2009 Mar;28(3):204-9.
Judd A et al. Effect of tenofovir disoproxil fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS. 2010 Feb 20;24(4):525-34.
Soler-Palacín P et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens.
AIDS. 2011 Jan 14;25(2):171-6.
Pontrelli G et al. Renal function in HIV-infected children and adolescents treated with tenofovir disoproxil fumarate and protease inhibitors.
BMC Infect Dis. 2012 Jan 23;12:18.
Purswani M et al. Tenofovir treatment duration predicts proteinuria in a multiethnic United States Cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J.2013 May;32(5):495-500.
Giacomet V et al. Long-term renal effects of tenofovir-disoproxil-fumarate in vertically HIV-infected children, adolescents, and young adults: a 132-month follow-up study. Clin Drug Investig. 2015 Jul;35(7):419-26.
Lim Y et al. Tenofovir-Associated Nephrotoxicity in Children with Perinatally-Acquired HIV Infection: A Single-Centre Cohort Study. Clin Drug Investig. 2015 May;35(5):327-33.
Della Negra M et al. Long-term efficacy and safety of tenofovir disoproxil fumarate in HIV-1-infected adolescents failing antiretroviral therapy:the final results of study GS-US-104-0321. Pediatr Infect Dis J. 2015 Apr;34(4):398-405.
Grignolo S et al. Trend of eGFR in an Italian cohort of mother-to-child HIV-infected patients exposed to tenofovir for at least 2 years. Eur J Pediatr. 2015 Jun;174(6):843-6.
Aurpibul L et al. Efficacy, safety and pharmacokinetics of tenofovir disoproxil fumarate in virologic-suppressed HIV-infected children using weight-band dosing. Pediatr Infect Dis J. 2015 Apr;34(4):392-7.
Bunupuradah T et al. Prevalence of Persistent Renal Dysfunction in Perinatally HIV-infected Thai Adolescents. Pediatr Infect Dis J. 2018 Jan;37(1):66-70.
